Panel voted against MDMA for PTSD due to doubts on effectiveness and risks, unlikely to gain FDA approval. Existing limited use in Australia for PTSD and depression.
Concerns raised included the inability to conduct double-blind studies, potential cardiovascular effects, abuse risks, and flaws in data impacting FDA decision.
[
Collection
]
[
|
...
]